
What is claimed is:

1. Use of a pharmaceutical composition in the manufacture of a medicament for (i) treating HFpEF and/or (ii) treating and/or preventing at least one disease, disorder, or condition associated with HFpEF, wherein the pharmaceutical composition is to be administered to a non-diabetic patient in need thereof, wherein the pharmaceutical composition comprising a therapeutically effective amount of at least one compound chosen from compounds of Formula (I)




,

(I)

wherein the at least one disease, disorder, or condition associated with HFpEF is chosen from skeletal muscle dysfunction, vascular dysfunction, hypertension, pulmonary hypertension, renal failure, anemia, atrial fibrillation, and major adverse cardiovascular events, wherein the major adverse cardiovascular event is chosen from myocardial infarction, stroke, cardiovascular death, and cardiovascular hospitalization,

wherein the non-diabetic patient is human, has HFpEF, and has a hemoglobin A1c of <5.7%, and

wherein the medicament is capable of further improving heart failure-related symptoms measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).

2. The use of claim 1, wherein the medicament is for treating HFpEF.

3. The use of claims 1 or 2, wherein the pharmaceutical composition further comprises at least one other therapeutic agent.

4. The use of claims 1 or 2, wherein the pharmaceutical composition is to be administered in combination with at least one other therapeutic agent.

5. The use of claim 4, wherein the at least one other therapeutic agent is to be administered before, after, or concurrently with the pharmaceutical composition.

6. The use of any of claims 3 to 5, wherein the at least one other therapeutic agent is chosen from antidiabetic agents, anti-obesity agents, anti-hyperlipidemic agents, anti-atherosclerotic agents, anti-hypertensive agents, anti-platelet agents, antithrombotic agents and anticoagulant agents.

7. The use of claim 6, wherein the at least one other therapeutic agent is chosen from biguanides and/or DPP4 inhibitors.

8. The use of claim 7, wherein the biguanide is metformin or a pharmaceutically acceptable salt thereof.

9. The use of claim 7, wherein the DPP4 inhibitor is saxagliptin or a pharmaceutically acceptable salt thereof.

10. The use of claim 7, wherein the at least one other therapeutic agent is metformin or a pharmaceutically acceptable salt thereof and saxagliptin or a pharmaceutically acceptable salt thereof.

11. The use of any of claims 1 to 10, wherein the pharmaceutical composition is suitable for oral administration.


12. The use of claim 11, wherein the pharmaceutical composition is in the form of a tablet.

13. The use of any of claims 1 to 12, wherein the at least one compound is in the form of a pharmaceutically acceptable solvate, mixed solvate, or complex.

14. The use of any of claims 1 to 13, wherein the at least one compound is in the form of a non-crystalline solid.

15. The use of any of claims 1 to 13, wherein the at least one compound is in the form of a crystalline solid.

16. The use of any of claims 1 to 15, wherein the at least one compound is in the form of a (S)-propylene glycol ((S)-PG) solvate which has the structure




17. The use of any of claims 1 to 16, wherein the pharmaceutical composition comprises a dose equivalent of about 2.5 mg/day, 5 mg/day, or 10 mg/day dapagliflozin.

18. The use of any of claims 1 to 16, wherein the pharmaceutical composition comprises a dose equivalent of about 10 mg/day dapagliflozin.

19. The use of any of claims 1 to 18, wherein the pharmaceutical composition is to be administered once daily.